Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Although these findings highlight integrin inhibitors as a viable class of ECM-targeted therapeutics, the majority of candidates remain at the preclinical or early clinical stage, and unresolved issues-including off-target toxicity, uncertainties in dose optimization, and limitations in delivery strategies pose substantial barriers to successful clinical translation (174)
Malliaras P, Barton CJ, Reeves ND, Langberg H
CJC-1295 Dosage: On average patients are taking 100-300mcg of CJC-1295 daily
These structural modifications are designed to enhance peptide stability, resistance to enzymatic degradation, and receptor interaction consistency in laboratory research environments
.png)
US$ 25.23
US$ 25.26
US$ 27.34
